The state pharma’s targeting this election cycle

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.

Pharma locks in on North Carolina

The pharmaceutical industry has lost some longtime allies in recent years. By the looks of it, executives and lobbyists are looking to North Carolina to make some new ones, according to federal campaign finance disclosures. Recall that a freshman Democratic lawmaker from North Carolina, Rep. Don Davis, was willing to stick his neck out and sponsor a policy to water down Democrats’ drug pricing reform bill earlier this year.

Another North Carolina Democrat caught industry’s eye last quarter: Rep. Deborah Ross, who is a member of House Democratic leadership as chief deputy whip and is on the caucus’ steering and policy committee. Ross received campaign donations in May from the CEOs of Merck, Eli Lilly, Biogen, Gilead, Bristol Myers Squibb, Genentech, and UCB, as well as a donation from PhRMA’s COO and PAC contributions from Eisai and Genentech.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In